Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07448038) titled 'A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events' on Feb. 25.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Genentech, Inc.
Condition:
Atherosclerosis
Intervention:
Drug: Selnoflast
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment:...